Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
NextCure's Capital Expenditure for the
three
months ended in Dec. 2024 was $0.03 Mil. Its Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil.
GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.
NextCure Capex-to-Revenue Historical Data
The historical data trend for NextCure's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NextCure's Capex-to-Revenue
For the Biotechnology subindustry, NextCure's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where NextCure's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (NAS:NXTC) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
NextCure Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of NextCure's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NXTC has been successfully added to your 